HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of intralesional 32-P chromic phosphate in refractory patients with head and neck tumours.

AbstractBACKGROUND:
The clinical outcome of refractory head and neck (H&N) cancer patients remains poor despite novel treatment strategies. In this pilot study the efficacy of intratumoral injection of 32-P chromic phosphate in 14 patiehts with refractory H&N carcinomas was investigated in terms of response rates and overall survival.
PATIENTS AND METHODS:
Fourteen patients (median age: 59 years) with either cytostatic drug-resistant tumours or tumours known to be primarily chemotherapy-resistant were entered into the study. After sonographic determination of the tumour volume, 32-P chromic phosphate (74-444 MBq) was injected into the central part of the tumour under sonographic guidance. Follow-up investigations included serial scintigraphy, sonographic examinations and hematological studies.
RESULTS:
Injection of 32-P chromic phosphate into refractory H&N tumours resulted in remarkable regression. The median survival of all patients was 7.8 months (range: 4-16). Eight patients exhibited a partial response, while 6 patients did not respond to the treatment. In 3 patients thrombocytopenia (grade I/II) was observed, but no other significant side-effects were apparent. Significant pathological and anatomical changes within the tumour tissue were demonstrated. In all cases examined, formation of a cyst within the area of central activity, surrounded by a centrifugal necrotic ring and a marginal fibrotic structure, was found.
CONCLUSION:
A lack of persistent systematic or local side-effects, as well as noteworthy efficacy, are properties of this novel regional treatment modality with 32-P chromic phosphate. This modality deserves consideration for further clinical trials.
AuthorsKyrus A Alimi, Nosrat Firusian, Wolfram Dempke
JournalAnticancer research (Anticancer Res) 2007 Jul-Aug Vol. 27 Issue 4C Pg. 2997-3000 ISSN: 0250-7005 [Print] Greece
PMID17695485 (Publication Type: Journal Article)
Chemical References
  • Chromium Compounds
  • Phosphates
  • Radiopharmaceuticals
  • chromic phosphate, 32P-labeled
Topics
  • Adult
  • Aged
  • Chromium Compounds (administration & dosage, adverse effects, pharmacokinetics)
  • Head and Neck Neoplasms (metabolism, pathology, radiotherapy)
  • Humans
  • Injections, Intralesional
  • Middle Aged
  • Phosphates (administration & dosage, adverse effects, pharmacokinetics)
  • Radiopharmaceuticals (administration & dosage, adverse effects, pharmacokinetics)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: